title: [In vitro evaluation on the effects of combined lamivudine (3TC) and Ara-AMP against hepatitis B virus].
abstract: BACKGROUND
  To evaluate the inhibitive effect of combination of 3TC with Ara-AMP against HBV in vitro.
  
  
  METHODS
  Used 2.2.15 cell as target cell. With radioimmunological technique and blot slot, the inhibitive effect of 3TC, Ara-AMP and the combination of both against the HBsAg, HBeAg and intracellular HBV DNA were investigated.
  
  
  RESULTS
  The inhibitive ratio of Ara-AMP against HBsAg, HBeAg was 45.48% and 41.46% respectively when its concentration was 400.0 microgram/ml. Although 3TC also has inhibitive effect in its experimental concentration, its effect is weaker. When Ara-AMP 50.0 microgram/ml was combined with 3TC 1.25 and 5.00 microgram/ml respectively, the inhibitive ratio against HBsAg were 19.92% and 17.32% respectively. Compared with using same concentration 3TC alone, the difference of results was significant (P<0.05). But when compared with using the same concentration Ara-AMP alone, the difference of results had no statistical significance (P <0.05). Remarkable inhibitive effects of combination of 3TC with Ara-AMP against HBeAg were n ot found. When 3TC 5.00 microgram/ml was combined with Ara-AMP 12.5 and 50.0 microgram/ml respectively, the inhibitive ratio against HBV DNA was 45.90% and 50.36% respectively. Comparing the content of HBV DNA in these groups with that of control group and the groups using the same concentration 3TC and Ara-AMP alone, the differences were significant (P <0.05).
  
  
  CONCLUSIONS
  Combination of 3TC with Ara-AMP could enhance the inhibitive effects against HBV DNA.
authors: 302nd Hospital of PLA, Beijing 100039, China.
authors: Haibin
authors: H
authors: Su
authors: Huifen
authors: H
authors: Wang
authors: Wei
authors: W
authors: Ji
authors: Yanling
authors: Y
authors: Zhao
authors: Guangming
authors: G
authors: Cai
mesh_terms: D000998:Antiviral Agents / Q000494:pharmacology*; D004279:DNA, Viral / Q000187:drug effects / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D006515:Hepatitis B virus / Q000187:drug effects*; D006801:Humans; D066298:In Vitro Techniques; D019259:Lamivudine / Q000494:pharmacology*; D001084:Vidarabine Phosphate / Q000494:pharmacology*
chemical_list: D000998:Antiviral Agents; D004279:DNA, Viral; D001084:Vidarabine Phosphate; D019259:Lamivudine